Real-World study tracks Nivolumab's impact on advanced stomach and esophageal cancers

NCT ID NCT07663786

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study looks at how the immunotherapy drug nivolumab is used in routine care for adults with advanced cancers of the esophagus, gastroesophageal junction, or stomach. Researchers will analyze data from a Dutch cancer registry to see how long people live after starting nivolumab and what factors affect their outcomes. The goal is to understand how well the drug works outside of clinical trials, in everyday hospital settings.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
nivolumab
What this could lead to
If successful, this could show how well nivolumab works in everyday practice for advanced stomach and esophageal cancers, helping doctors make better treatment decisions.
What could go wrong
This is an observational study using existing data, not a controlled trial. It cannot prove cause and effect, and results may be influenced by factors like patient selection or missing information.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Amsterdam UMC

    Amsterdam, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.